

Figure S1. Kaplan-Meier curves for overall survival in the lenvatinib, sorafenib and TACE groups. TACE, transarterial chemoembolization.




Figure S2. Kaplan-Meier curves for the medication period with lenvatinib in the ALBI grade 1 and 2 groups. ALBI, albumin-bilirubin.

